About
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.
Team & affiliation
Founders: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object].
Region context
Lacerta Therapeutics is one of 3 Biotechnology companies we track in Gainesville / North Central, based in Alachua — about 20% of the region's 15 startups.
Gainesville — a UF-anchored research corridor strong in biotech, medtech, and university spinouts.
See the full Gainesville / North Central ecosystem →